Company News

New European Software Release - MyoStrain® 5.2.4

June 10, 2022
Company News

MORRISVILLE, N.C., June 10, 2022 – Myocardial Solutions released a new software version of MyoStrain® with a primary new function feature enabling semi-auto contouring of cardiac images.

While all images must be reviewed for accuracy by a physician, the new feature, utilizing artificial intelligence, helps provide even stronger consistency of outcomes between operators and MRI manufacturers.

All European sites have upgraded to the new version and have expressed enthusiasm for the semi-auto contouring feature.

Media Contact

About Myocardial Solutions, Inc.

Myocardial Solutions, Inc. (MSI) is a medical technology company working to transform the cardiac and cancer care continuum. Leveraging more than 400 publications in clinical research and development, MSI’s proprietary technology, MyoStrain®, is a 10-minute, MRI-based heart function test providing physicians with sensitive diagnostic markers to support the early assessment and individualized treatment of heart dysfunction. MyoStrain has received FDA-510(k) pre-market clearance, CE-mark certification, and is commercially available in the United States and Europe.

To learn more about MyoStrain, visit or connect with us on LinkedIn and Twitter @myocardialsoln.  

808 Aviation Pkwy, Suite 700 | Morrisville, NC 27560 | | ph: +1.919.677.8100

© Copyright 2022 Myocardial Solutions Inc. All rights reserved. MyoStrain® and the MyoHealthTM 
Score are among the trademarks of Myocardial Solutions.